Kairos Pharma, LTD. (KAPA) AI Dilution Summary

Cash was $2,626,000 at the 2026-06-30 balance-sheet date, against estimated monthly burn of $341,333. The company's funding channel is its ATM with H.C. Wainwright & Co., LLC, authorised to $4,524,949, which has sold 423,039 shares since the program began. Of those, 337,047 shares were sold after the 2026-06-30 balance-sheet date and through 2026-08-12, raising $883,670 net; sales after 2026-08-12 are not yet reported.